Knight Therapeutics Inc. Sustainability Profile
Knight Therapeutics Inc., a prominent Canadian biopharmaceutical company, is headquartered in Montreal, Quebec. Founded in 2014, Knight Therapeutics focuses on the acquisition, development, and commercialisation of innovative pharmaceutical products, primarily in the areas of oncology, infectious diseases, and rare diseases. With a commitment to addressing unmet medical needs, the company has established a strong market position through strategic partnerships and a robust pipeline of unique therapies. Knight Therapeutics is recognised for its dedication to patient-centric solutions, offering a range of products that stand out for their efficacy and safety profiles. As a leader in the biopharmaceutical industry, Knight Therapeutics continues to make significant strides in improving health outcomes across Canada and beyond.
DitchCarbon Score
How does Knight Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Knight Therapeutics Inc.'s score of 28 is lower than 53% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Knight Therapeutics Inc.'s reported carbon emissions
Knight Therapeutics Inc., headquartered in Canada, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Knight Therapeutics Inc. does not inherit emissions data from any parent or related organizations, and there are no commitments to industry-standard initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). In the context of climate commitments, it is essential for companies in the pharmaceutical sector to establish clear emissions reduction strategies and transparency in reporting to align with global climate goals. However, without specific data or commitments, Knight Therapeutics Inc. remains unquantified in its climate impact and initiatives.
How Carbon Intensive is Knight Therapeutics Inc.'s Industry?
How Carbon Intensive is Knight Therapeutics Inc.'s Location?
Knight Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Knight Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
